Lebedeva I.S.,Mental Health Research Center
Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova | Year: 2015
Objective. The search of the structural and functional brain characteristics is one of the most studied directions in the modern biological psychiatry. However, in spite of the numerous studies the results are still controversial. As the necessity of the shift of the current paradigm in schizophrenia research evolves it has been suggested to discriminate not only abnormal but stable functioning neuronal circuits as well. Consequently, the aim is formulated as the search of the minimal brain damage sufficient for disease development. Material and methods. Author analyzed the auditory oddball P300 latency (as a marker of information processing speed), N-acetylaspartate level in the dorsolateral prefrontal cortex (as a marker of neuronal integrity in this brain area) and fractional anisotropy of the fasciculus uncindtus which connects the frontal and temporal lobes (as a marker of white matter bundles microstructure) in 30 patients with schizophrenia and 27 healthy people. Results and conclusion. The findings showed that all the tested characteristics are not «obligatory» for schizophrenia. © 2015, Media Sphera. All rights reserved.
Golimbet V.E.,Mental Health Research Center
Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova | Year: 2016
Advanced genome technologies, including genome-wide association studies, next generation sequencing analysis, whole exome sequencing, encourage the development of theoretical insights on the role of genetic factors in schizophrenia. In this context, the author considers a monogenic model of schizophrenia and its evolution. © 2016, Media Sphera. All rights reserved.
Pelayo-Teran J.M.,University of Cantabria |
Pelayo-Teran J.M.,Centro Investigacion Biomedica en Red Salud Mental |
Diaz F.J.,University of Kansas Medical Center |
Perez-Iglesias R.,University of Cantabria |
And 8 more authors.
Psychological Medicine | Year: 2014
Background Trajectory patterns of positive, disorganized and negative dimension symptoms during antipsychotic treatment in drug-naive patients with first-episode psychosis have yet to be examined by using naturalistic data. Method This pragmatic clinical trial randomized 161 drug-naive patients with a first episode of psychosis to olanzapine, risperidone or haloperidol. Patients were assessed with the Scale for the Assessment of Negative Symptoms (SANS) and Positive Symptoms (SAPS) at baseline and at the end of weeks 1, 2, 3, 4 and 6 of antipsychotic treatment. Censored normal models of response trajectories were developed with three dimensions of the SAPS-SANS scores (positive, disorganized and negative) in order to identify the different response trajectories. Diagnosis, cannabis use, duration of untreated psychosis (DUP), smoking and antipsychotic class were examined as possible predictive variables. Results Patients were classified in five groups according to the positive dimension, three groups according to the disorganized dimension and five groups according to the negative dimension. Longer DUPs and cannabis use were associated with higher scores and poorer responses in the positive dimension. Cannabis use was associated with higher scores and poorer responses in the disorganized dimension. Only schizophrenia diagnosis was associated with higher scores and poorer responses in the negative dimension. Conclusions Our results illustrate the heterogeneity of short-term response to antipsychotics in patients with a first episode of psychosis and highlight markedly different patterns of response in the positive, disorganized and negative dimensions. DUP, cannabis use and diagnosis appeared to have a prognostic value in predicting treatment response with different implications for each dimension. © 2013 Cambridge University Press.
Hough D.,Johnson and Johnson Pharmaceutical Research and Development LLC |
Gopal S.,Johnson and Johnson Pharmaceutical Research and Development LLC |
Vijapurkar U.,Johnson and Johnson Pharmaceutical Research and Development LLC |
Lim P.,Johnson and Johnson Pharmaceutical Research and Development LLC |
And 2 more authors.
Schizophrenia Research | Year: 2010
Objective: We assessed efficacy and tolerability of the injectable atypical antipsychotic paliperidone palmitate in delaying time-to-relapse in adults with schizophrenia. Methods: Eligible patients (Positive and Negative Syndrome Scale [PANSS] total score < 120) were transitioned from previous antipsychotics to paliperidone palmitate during a 9-week, open-label phase. Patients received the first 2 intramuscular injections of paliperidone palmitate (50 mg eq) one-week apart, then subsequent injections (25, 50, or 100 mg eq, flexibly-dosed), once-monthly. Stable patients (PANSS total score ≤ 75) continued into the 24-week maintenance phase. At maintenance phase endpoint, stabilized patients were randomized (1:1 ratio) to either continue paliperidone palmitate (at stabilized dose) or begin placebo in the variable-duration, double-blind phase. Results: The preplanned interim analysis (conducted after 68 relapse events) included 312 patients: mean age = 40 years, 55% men, 66% white, and mean transition baseline PANSS total score (SD): placebo, 69.5 (16.89); paliperidone palmitate, 69.3 (17.39). Time-to-relapse (primary endpoint) favored paliperidone palmitate (p < 0.0001, log-rank test) at interim and final analysis (n = 408). The hazard ratio (placebo/paliperidone palmitate) at the final analysis was 3.60 (95% CI: 2.45, 5.28). Treatment-emergent adverse event rates (final analysis set) were: 67% for transition and maintenance phases, and 45% (placebo) and 44% (paliperidone palmitate) for the double-blind phase. Across phases, the incidence of glucose-related adverse events was low (≤ 4%), while mean weight increased by 1.9 kg for paliperidone palmitate and remained unchanged for placebo patients. Injection site tolerability was comparable between groups. Conclusion: Paliperidone palmitate significantly delayed time-to-relapse compared with placebo and presented no new safety signals. © 2009 Elsevier B.V. All rights reserved.
Barkhatova A.N.,Mental Health Research Center
Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova | Year: 2015
Objective. To study the structure of deficit disorders identified in the initial phase (first 5 years) of youth-onset endogenous psychosis. Materials and methods. Author examined 232 patients with the first episode of juvenile endogenous psychosis during the period from 2005 to 2015 using integrated phenomenological and clinical/psychopathological approaches. The follow-up was administered to 151 patients. Results and conclusion. The working hypothesis on the formation of deficit symptom variants based on the mutual competition of its components was formulated. Identified typological species allowed to hypothesize the existence of continual series of variations of deficit disorders manifested as phenomena with multilateral dependencies, characterized by dynamism and a wide range of modifications and verifiable in remission at the initial stages of attack-like endogenous psychosis. © 2015, Media Sphera. All rights reserved.